By David Bautz, PhD
Sophiris Bio Inc. (SPHS) is developing treatments for localized clinically significant prostate cancer and lower urinary tract symptoms of benign prostatic hyperplasia (BPH). The company’s lead candidate, topsalysin (PRX302), is a genetically engineered recombinant protein that is activated through enzymatic cleavage by prostate specific antigen (PSA), which is produced in large quantities by the prostate gland. Once activated, topsalysin self-aggregates to form stable transmembrane pores and initiate cell death. The compound has been successfully tested in one Phase 3 clinical trial for BPH and a Phase 2a clinical trial for localized prostate cancer.
Phase 2b Trial Topline Results in 2Q18
Sophiris is currently conducting a Phase 2b clinical trial of topsalysin in patients with localized clinically significant prostate cancer (NCT03081481). A clinically significant tumor is defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL.
On Dec. 11, 2017, the company announced that the trial completed enrollment. Six months following treatment with topsalysin, a targeted biopsy will be performed of the treated area, thus we anticipate that all biopsy data will be available toward the end of the second quarter of 2018. The study includes an option to re-treat the targeted lesion with a second dose of topsalysin, followed by a second targeted biopsy six months following the second dose. In order to receive a second dose, a patient cannot have experienced a significant adverse event attributable to topsalysin or the dosing procedure and the patient will need to have had a clinical response from the first dose but still have a clinically significant lesion. Final biopsy data from all patients who receive a second dose of topsalysin will be available in the fourth quarter of 2018.
The company has initiated informal discussions with regulatory authorities in Europe as part of planning for a Phase 3 registration study. There is more regulatory experience with targeted focal therapy for patients with localized prostate cancer in Europe, thus the company is hoping to gain insight into the proper design of any future clinical trials. In addition, manufacturing activities have begun to prepare enough topsalysin for use in a potential Phase 3 studies in prostate cancer and BPH.
Proaerolysin is an inactive precursor protein secreted by the Aeromonas genus of Gram-negative, anaerobic bacteria (Buckley, 1992). Once released by the bacterium, proaerolysin binds to the surface of target cells, where it is cleaved by furin-like proteases to produce aerolysin (Abrami et al., 1998). Activation of aerolysin results in the formation of a heptameric oligomer that inserts into the cell membrane forming a transmembrane pore. Loss of small molecules and ions through the channels eventually leads to cell death.
The specific cleavage of proaerolysin is due to the presence of the furin cleavage sequence KVRRAR located within the protein. Furin is a ubiquitous protease that is produced by most cell types, thus native proaerolysin can be activated throughout the body. In order to target the molecule to the prostate for use as a potential therapeutic agent, the furin cleavage sequence was replaced with a prostate specific antigen (PSA)-selective cleavage sequence HSSKLQ (Denmeade et al., 1997). PSA is a protease produced by the prostate gland, and while it is found in the bloodstream, the vast majority of circulating PSA is bound by protease inhibitors and thus is enzymatically inactive (Christensson et al., 1990). Enzymatically active PSA is found almost exclusively in normal and malignant prostate tissue (Olsson et al., 2005).
Prostate cancer is the most common non-cutaneous cancer diagnosed in men. It is typically a slow growing cancer, although it still accounts for approximately 10% of all cancer related deaths in men. Currently, most of the cases of prostate cancer are found through routine screening of prostate specific antigen (PSA) level, although some cases are also identified as an incidental pathological finding when tissue is removed during transurethral resection to manage obstructive prostatic symptoms.
The American Cancer Society estimates that approximately 161,000 men will be diagnosed with prostate cancer in 2017, while approximately 26,730 men will die from the disease (SEER database). Approximately 80% of those diagnosed will have localized disease. Half of those will have low-risk disease that is unlikely to ever spread outside of the prostate, however the other half of those with localized disease will have intermediate- or high-risk disease that is more suited to treatment.
The disease is quite rare in men less than 40 years of age and is still uncommon in men younger than 50. Sixty percent of cases are in men aged 65 or older and the average age of diagnosis is 66. Prevalence rates are significantly higher in African-Americans than in White or Hispanic populations, although the exact reasons for this are unclear (Hoffman et al., 2001). In addition to age and race, other risk factors include geography, as most cases occur in North American, Northwestern Europe, Australia, and the Caribbean Islands, and genetics, as prostate cancer appears to run in some families.
Topsalysin in Localized Prostate Cancer
Treating prostate cancer with topsalysin is possible due to the high levels of enzymatically active PSA that surround prostate lesions. In addition, MRI imaging can be combined with real-time 3D ultrasound in order to target the treatment specifically to a histologically proven, clinically significant lesion, thus sparing surrounding healthy prostate tissue and offering a more favorable safety profile.
Thus far topsalysin has been tested in a proof-of-concept Phase 2a clinical study in patients with localized low-to-intermediate risk prostate cancer (NCT02499848). It was a single center, open label, six-month study in 18 men that were administered topsalysin to treat a single, histologically proven, clinically significant lesion. Patients needed to have a Gleason score of 7 and ≤ 10 mm Maximum Cancer Core Length (MCCL) or a Gleason score of 6 and > 3 mm MCCL. The primary outcome of the study was safety and tolerability over six months with secondary outcomes examining histological and MRI evidence of tumor control over six months.
Results from the study showed that two men experienced complete ablation of their targeted tumor with no evidence of tumor remaining at six months, nine men experienced a partial response, defined as either a reduction in the MCCL or a reduction in Gleason pattern, and seven patients had no response to treatment. The results are all summarized in the following graph.
Two very important findings from the Phase 2a study were identified in relation to dosing and administration of topsalysin that could lead to greater efficacy in future clinical trials:
‣ Topsalysin was administered at a dose of 5 μg/g of prostate tissue. One of the key findings from the Phase 2a trial was that dosing should be performed based on the size of the tumor, not the prostate. An analysis of treatment response based on the size of the tumor for the Phase 2a trial showed that most of the responders in the study received > 500 μg topsalysin/g of tumor while for those that did not respond most received < 500 μg topsalysin/g of tumor.
‣ The delivery of topsalysin will be optimized in future trials by using a spring needle such that the drug can be administered slowly, thus allowing it to diffuse into the tumor cells and surrounding regions. The company reported that some of the patients in the Phase 2a study had tumors that were very dense, and when the drug was injected it was not able to properly saturate the tumor. By decreasing the rate at which the drug is injected, the company believes that topsalysin will be more likely to stay in the tumor microenvironment and fully penetrate the tumor tissue.
The fact that two patients saw a complete response in the proof-of-concept clinical trial is very encouraging, as the study was only designed to allow for a greater understanding of the optimal dose and delivery method for topsalysin. Based on the data obtained thus far, we believe that topsalysin could offer men with low-to-intermediate risk prostate cancer the potential to have their lesion ablated, or at least decreased to a size that warrants active surveillance as opposed to radical treatment (e.g., radical prostatectomy).
On May 14, 2018, Sophiris announced financial results for the first quarter of 2018. As expected, the company did not report any revenues. For the first quarter of 2018, Sophiris reported a net loss of $3.3 million, or $0.11 per share, compared to a net loss of $2.6 million, or $0.09 per share, for the first quarter of 2017. Research and development expenses were $3.3 million for the first quarter of 2018 compared to $1.2 million for the first quarter of 2017. The increase in R&D expenses was primarily due to increased manufacturing costs for topsalysin along with an increase in clinical costs associated with the Phase 2b clinical trial. G&A expenses were $1.2 million for the first quarter of 2018 compared to $1.4 million for the first quarter of 2017. The decrease was primarily due to decreased stock-based compensation.
As of March 31, 2018, Sophiris had approximately $22.1 million in cash and cash equivalents. We believe Sophiris’ current cash is sufficient to fund operations to mid-2019, which is after the expected final data from the Phase 2b trial. As of March 8, 2018, Sophiris had approximately 30.1 million common shares outstanding and when factoring in options and warrants a fully diluted share count of approximately 38.8 million.
We value Sophiris using a probability adjusted discounted cash flow that takes into account potential future revenues from the sale of topsalysin in both BPH and prostate cancer. For both BPH and prostate cancer, we anticipate the company ultimately entering into collaboration before commercialization of topsalysin. For modeling purposes, we are estimating a second Phase 3 study starting in BPH in 2019 and approval in 2022. For prostate cancer, we estimate a Phase 3 program completing by 2021 and approval in 2022. We believe that topsalysin could attain 20% market share and have peak revenues of approximately $950 million in the U.S. and $850 million in the E.U. Using a 15% royalty rate, a 13% discount rate, and a 40% chance of approval, we estimate the net present value for topsalysin in prostate cancer to be $201 million. For BPH, we model for a low market share for the approximately 4 million men who receive treatment for BPH and peak revenues of approximately $300 million. Using a 15% royalty rate, a 13% discount rate, and a 60% chance of approval, we estimate the net present value for topsalysin in BPH to be $52 million.
Combining the values for topsalysin in prostate cancer and BPH along with the company’s current cash total and expected additional capital leads to a net present value for the company of $249 million. Dividing this number by the fully diluted share count of approximately 38.8 million shares leads to a valuation of approximately $6, and we note considerable upside is possible to this valuation with continued clinical success of topsalysin in the company’s Phase 2b trial in prostate cancer.
READ THE FULL RESEARCH REPORT HERE.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.